Souhaitez-vous accéder aux communiqués récents ?

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results...

Xunxi brings RMB 340 million in audited 2025 revenue, 200+ institutional clients, and a 2 million-member digital commerce platform.

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Dubai, UAE, March 23, 2026 (GLOBE NEWSWIRE) -- New crypto Pepeto team announces that the project advancement is nearing launch, and it just crossed $8.3 million because experienced crypto investors...

CALGARY, Alberta, March 23, 2026 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company"), a specialty construction contractor that produces cellular...

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the...

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

Phoenix Energy launches an updated Bondholder Portal with enhanced usability and new features to support its growing base of 6,000+ investors.

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and...